{"id":"matching-placebo-for-dapagliflozin","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a matching placebo for dapagliflozin, this formulation is designed to be indistinguishable in appearance and administration from the active drug but contains no active ingredient. It is used in clinical trials to provide a control arm for comparison against the active SGLT2 inhibitor dapagliflozin.","oneSentence":"This is a placebo control formulation with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:15.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials of dapagliflozin"}]},"trialDetails":[{"nctId":"NCT06742723","phase":"PHASE3","title":"A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-03","conditions":"Chronic Kidney Disease and Hypertension","enrollment":5000},{"nctId":"NCT06307652","phase":"PHASE3","title":"Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-12","conditions":"Heart Failure and Impaired Kidney Function","enrollment":4800},{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46},{"nctId":"NCT07280585","phase":"PHASE3","title":"STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2025-12-16","conditions":"Polycystic Kidney, Autosomal Dominant","enrollment":420},{"nctId":"NCT06907251","phase":"PHASE3","title":"Dapagliflozin for Long COVID Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2026-04-01","conditions":"COVID - 19, Long COVID Syndrome, SARS CoV-2","enrollment":192},{"nctId":"NCT06677060","phase":"PHASE3","title":"Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-14","conditions":"Heart Failure","enrollment":11300},{"nctId":"NCT07323524","phase":"PHASE4","title":"Dapagliflozin in Active Lupus Nephritis","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-01","conditions":"Lupus Nephritis (LN)","enrollment":33},{"nctId":"NCT06268873","phase":"PHASE3","title":"A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-29","conditions":"Chronic Kidney Disease and Hypertension","enrollment":2554},{"nctId":"NCT05179356","phase":"PHASE2","title":"Dapagliflozin in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Mads Ersbøll","startDate":"2023-01-01","conditions":"Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension","enrollment":52},{"nctId":"NCT06269484","phase":"PHASE2","title":"A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-15","conditions":"Liver Cirrhosis","enrollment":73},{"nctId":"NCT07174687","phase":"PHASE2","title":"SGLT2 Inhibitors in Geographic Atrophy","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-12-02","conditions":"Retinal Degeneration, Retinal Diseases, Eye Diseases","enrollment":70},{"nctId":"NCT05374291","phase":"PHASE3","title":"The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Center Groningen","startDate":"2022-11-08","conditions":"Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure","enrollment":1750},{"nctId":"NCT07245069","phase":"PHASE2","title":"Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-02-01","conditions":"Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD)","enrollment":100},{"nctId":"NCT05468203","phase":"PHASE3","title":"PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care","status":"RECRUITING","sponsor":"The George Institute","startDate":"2023-11-29","conditions":"Acute Kidney Injury","enrollment":3000},{"nctId":"NCT05516498","phase":"PHASE2","title":"Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-10-31","conditions":"Liver Cirrhosis","enrollment":205},{"nctId":"NCT06054035","phase":"PHASE4","title":"SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-10-26","conditions":"Type2diabetes, PreDiabetes, Renal Failure","enrollment":170},{"nctId":"NCT04363697","phase":"PHASE4","title":"Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)","status":"COMPLETED","sponsor":"The TIMI Study Group","startDate":"2020-09-24","conditions":"Acute Heart Failure, Heart Failure","enrollment":2401},{"nctId":"NCT03919656","phase":"PHASE4","title":"SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2019-05-12","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT05590143","phase":"PHASE4","title":"proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amsterdam UMC","startDate":"2023-06-09","conditions":"Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor","enrollment":784},{"nctId":"NCT06350123","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-05-01","conditions":"Chronic Kidney Disease","enrollment":324},{"nctId":"NCT05570305","phase":"PHASE2","title":"Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2022-10-06","conditions":"Chronic Kidney Diseases","enrollment":42},{"nctId":"NCT05852704","phase":"PHASE3","title":"SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-04","conditions":"Chronic Coronary Syndrome, Atrial Fibrillation","enrollment":800},{"nctId":"NCT04965935","phase":"PHASE3","title":"Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2021-07-15","conditions":"Kidney Transplant Recipients, Post-transplant Diabetes Mellitus, Type 2 Diabetes","enrollment":52},{"nctId":"NCT04564742","phase":"PHASE3","title":"Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-22","conditions":"Acute Myocardial Infarction, Heart Failure","enrollment":4017},{"nctId":"NCT04492722","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-10-01","conditions":"Chronic Kidney Disease","enrollment":613},{"nctId":"NCT04234867","phase":"PHASE1","title":"Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)","status":"TERMINATED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2022-05-18","conditions":"Type 1 Diabetes, Diabetic Ketoacidosis","enrollment":2},{"nctId":"NCT06304857","phase":"PHASE3","title":"CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL","status":"RECRUITING","sponsor":"4th Military Clinical Hospital with Polyclinic, Poland","startDate":"2024-04-15","conditions":"Breast Cancer, Heart Failure","enrollment":188},{"nctId":"NCT04869124","phase":"PHASE4","title":"Dapagliflozin on Volume Vascular Outcomes.","status":"COMPLETED","sponsor":"Frank Ruschitzka","startDate":"2021-02-15","conditions":"Heart Failure，Congestive","enrollment":80},{"nctId":"NCT05321706","phase":"PHASE3","title":"DAPAgliflozin for Renal Protection in Heart Transplant Recipients","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2022-06-08","conditions":"Heart Transplant Failure, Kidney Failure","enrollment":430},{"nctId":"NCT03199053","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT03190694","phase":"PHASE2","title":"Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria","status":"COMPLETED","sponsor":"Hiddo Lambers Heerspink","startDate":"2017-11-12","conditions":"Chronic Kidney Diseases, Proteinuria","enrollment":53},{"nctId":"NCT04249778","phase":"PHASE4","title":"Dapagliflozin at Discharge on Hospital Heart Failure Readmission","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-07-29","conditions":"Heart Failure, Diabetes","enrollment":105},{"nctId":"NCT03801642","phase":"PHASE1, PHASE2","title":"Dapagliflozin In Alzheimer's Disease","status":"COMPLETED","sponsor":"Jeff Burns, MD","startDate":"2019-01-29","conditions":"Alzheimer Disease","enrollment":46},{"nctId":"NCT06009874","phase":"NA","title":"Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI","status":"RECRUITING","sponsor":"Mohammad Hussien Tantawy Soliman","startDate":"2023-10","conditions":"Myocardial Infarction","enrollment":80},{"nctId":"NCT04258371","phase":"PHASE2","title":"DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2020-02-10","conditions":"Cardiovascular Risk Factor","enrollment":50},{"nctId":"NCT04080518","phase":"PHASE4","title":"Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Heart Failure","enrollment":40},{"nctId":"NCT03030235","phase":"PHASE4","title":"Dapagliflozin in PRESERVED Ejection Fraction Heart Failure","status":"COMPLETED","sponsor":"Saint Luke's Health System","startDate":"2017-03-01","conditions":"Chronic Heart Failure With Preserved Systolic Function","enrollment":324},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT02725593","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-22","conditions":"Type 2 Diabetes","enrollment":72},{"nctId":"NCT03423355","phase":"PHASE4","title":"Dapagliflozin Effect on Erythropoiesis and Physical Fitness","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2021-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT03721874","phase":"PHASE4","title":"Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation","status":"COMPLETED","sponsor":"Maastricht University","startDate":"2019-04-30","conditions":"Prediabetic State, Substrate Oxidation","enrollment":16},{"nctId":"NCT04219124","phase":"PHASE4","title":"The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2018-09-20","conditions":"Type 2 Diabetes","enrollment":9},{"nctId":"NCT03338855","phase":"PHASE4","title":"Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-03-05","conditions":"Diabetes Mellitus, Type 2, Skeletal Muscle Insulin Sensitivity","enrollment":26},{"nctId":"NCT02751398","phase":"PHASE4","title":"Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-08-18","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT02608905","phase":"PHASE4","title":"Effect of Dapagliflozin on Inflammation and Endothelial Function","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":17},{"nctId":"NCT03556033","phase":"PHASE2","title":"Effect of Dapagliflozin on IAH in T1DM","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2018-11-23","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness","enrollment":15},{"nctId":"NCT03180489","phase":"PHASE2","title":"Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?","status":"COMPLETED","sponsor":"Christopher Bell","startDate":"2017-05-03","conditions":"Weight Loss","enrollment":62},{"nctId":"NCT03444584","phase":"PHASE2","title":"Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2018-05-08","conditions":"Type 2 Diabetes Mellitus","enrollment":49},{"nctId":"NCT03316131","phase":"PHASE2","title":"A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-25","conditions":"Asymptomatic Hyperuricemia","enrollment":36},{"nctId":"NCT03364985","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-12-03","conditions":"Healthy","enrollment":123},{"nctId":"NCT02547935","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, CKD and Albuminuria","enrollment":459},{"nctId":"NCT02956811","phase":"PHASE4","title":"Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2017-02-14","conditions":"Type 2 Diabetes, Left Ventricular Hypertrophy","enrollment":66},{"nctId":"NCT02371187","phase":"PHASE2","title":"Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?","status":"COMPLETED","sponsor":"Christopher Bell","startDate":"2015-06","conditions":"Physical Activity","enrollment":37},{"nctId":"NCT02520518","phase":"PHASE2","title":"Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?","status":"TERMINATED","sponsor":"Christopher Bell","startDate":"2015-08","conditions":"Weight Loss","enrollment":9},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT02413398","phase":"PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-06-15","conditions":"Type 2 Diabetes Mellitus","enrollment":321},{"nctId":"NCT02426541","phase":"PHASE4","title":"Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":55},{"nctId":"NCT01137474","phase":"PHASE3","title":"A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-07","conditions":"Type 2 Diabetes","enrollment":2996},{"nctId":"NCT00528879","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Type 2 Diabetes","enrollment":915},{"nctId":"NCT01294423","phase":"PHASE3","title":"Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-02","conditions":"Type 2 Diabetes, High Blood Sugar","enrollment":261},{"nctId":"NCT00855166","phase":"PHASE3","title":"Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus","enrollment":182}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching Placebo for Dapagliflozin","genericName":"Matching Placebo for Dapagliflozin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control formulation with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trials of dapagliflozin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}